EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging and Newly Approved Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Narrative Review

Raghad Saeed Asiri iD, Khaled Abdulwahab Amer iD, Leen Abdulmohsin Sarhan, Najla Ahmad Jahash, Riham Hamoud Alharbi

Diseases · 31.07.2026 · 14 (8) · 276

DOI: 10.3390/diseases14080276 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diseases, online erschienen am 31.07.2026. Verfasst von Raghad Saeed Asiri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Aseer Central Hospital, Aseer Health Cluster, Abha 62523, Saudi Arabia. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic spontaneous urticaria (CSU) is a mast cell-driven disorder defined by recurrent wheals, angioedema, or both, persisting for longer than six weeks without an identifiable external trigger. Second-generation H1-antihistamines remain first-line therapy, yet a large share of patients stay symptomatic after the dose is raised up to fourfold, and for more than a decade, omalizumab was the only targeted option for those who failed antihistamines. This began to change in 2025, when the interleukin-4 receptor alpha (IL-4Rα) antagonist dupilumab and the oral, covalent Bruton tyrosine kinase (BTK) inhibitor remibrutinib were approved for antihistamine-refractory CSU within months of one another, while the anti-KIT monoclonal antibody barzolvolimab, which depletes mast cells, advanced into the largest phase 3 program the disease has seen. This narrative review outlines the guideline framework that still anchors CSU care, appraises the pivotal efficacy and safety data for omalizumab, dupilumab, remibrutinib, and barzolvolimab, and considers how these mechanistically distinct agents might be positioned and sequenced. The widening choice makes individualized, mechanism-informed treatment a realistic goal, but it also sharpens unresolved questions about patient selection, optimal treatment duration in a naturally remitting disease, and the long-term safety of newer oral and mast cell-depleting approaches.

Schlagwörter

Stichwörter der Autor:innen

Bruton tyrosine kinase inhibitorKITbarzolvolimabbiologic therapychronic spontaneous urticariadupilumabmast cellomalizumabremibrutinib

Autor:innen und Institutionen

  • Department of Internal Medicine, Aseer Central Hospital, Aseer Health Cluster, Abha 62523, Saudi Arabia.
  • Department of Immunology, Aseer Central Hospital, Aseer Health Cluster, Abha 62523, Saudi Arabia.
  • Department of Pharmacy, Hottat Bani Tamim General Hospital, Hotat Bani Tamim 17981, Saudi Arabia.

ORCID-Profile: Raghad Saeed Asiri, Khaled Abdulwahab Amer

Zitieren

APA

Asiri, R. S., Amer, K. A., Sarhan, L. A., Jahash, N. A., & Alharbi, R. H. (2026). Emerging and Newly Approved Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Narrative Review. Diseases, 14(8), 276. https://doi.org/10.3390/diseases14080276

Vancouver

Asiri RS, Amer KA, Sarhan LA, Jahash NA, Alharbi RH. Emerging and Newly Approved Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Narrative Review. Diseases. 2026;14(8):276. doi:10.3390/diseases14080276

BibTeX
@article{Asiri2026,
  author = {Asiri, Raghad Saeed and Amer, Khaled Abdulwahab and Sarhan, Leen Abdulmohsin and Jahash, Najla Ahmad and Alharbi, Riham Hamoud},
  title = {Emerging and Newly Approved Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Narrative Review},
  journal = {Diseases},
  year = {2026},
  volume = {14},
  number = {8},
  pages = {276},
  doi = {10.3390/diseases14080276}
}
Kostenlos starten →